Adamis Pharma Stock EBITDA
Adamis Pharma fundamentals help investors to digest information that contributes to Adamis Pharma's financial success or failures. It also enables traders to predict the movement of Adamis Stock. The fundamental analysis module provides a way to measure Adamis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adamis Pharma stock.
Adamis |
Adamis Pharma Company EBITDA Analysis
Adamis Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Adamis Pharma EBITDA | (24.27 M) |
Most of Adamis Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adamis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Adamis Pharma reported earnings before interest,tax, depreciation and amortization of (24.27 Million). This is 102.77% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 100.62% higher than that of the company.
Adamis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adamis Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adamis Pharma could also be used in its relative valuation, which is a method of valuing Adamis Pharma by comparing valuation metrics of similar companies.Adamis Pharma is currently under evaluation in ebitda category among its peers.
Adamis Fundamentals
| Return On Equity | -7.85 | |||
| Return On Asset | -1.04 | |||
| Operating Margin | (3.74) % | |||
| Current Valuation | 7.28 M | |||
| Shares Outstanding | 9.36 M | |||
| Shares Owned By Insiders | 7.81 % | |||
| Shares Owned By Institutions | 16.59 % | |||
| Number Of Shares Shorted | 98.94 K | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 8.62 X | |||
| Price To Sales | 17.64 X | |||
| Revenue | 4.76 M | |||
| Gross Profit | (1.43 M) | |||
| EBITDA | (24.27 M) | |||
| Net Income | (26.48 M) | |||
| Cash And Equivalents | 8.88 M | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 342.56 K | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 1.58 X | |||
| Book Value Per Share | (4.24) X | |||
| Cash Flow From Operations | (25.9 M) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (10.14) X | |||
| Target Price | 0.42 | |||
| Number Of Employees | 11 | |||
| Beta | 1.28 | |||
| Market Capitalization | 7.25 M | |||
| Total Asset | 10.93 M | |||
| Retained Earnings | (304.56 M) | |||
| Working Capital | (2.12 M) | |||
| Current Asset | 4.15 M | |||
| Current Liabilities | 2.75 M | |||
| Z Score | -33.43 | |||
| Net Asset | 10.93 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Adamis Stock
If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |